NEW YORK (GenomeWeb) – Swift Biosciences and Fluxion Biosciences have teamed up to develop a clinical oncology research workflow designed to detect somatic mutations from patient blood samples.
The jointly developed workflow uses Fluxion's IsoFlux system for circulating tumor cell enrichment along with Swift's Accel-Amplicon technology.
IsoFlux enriches rare tumor cells circulating in the blood using a combination of epithelial and mesenchymal markers, and delivers them at high purity for molecular analysis.
Meantime, Swift's Accel-Amplicon 56G Oncology Panel combines target enrichment, library preparation, and sequencing on Illumina platforms to provide sensitive mutation detection across 56 cancer-related genes using very low starting DNA inputs from the IsoFlux System.
The workflow and associated products are for research use only, the companies noted.